上海动漫音乐分享社区

Opdivo给药方式由两周一次(Q2W)扩展至四周一次(Q4W)

Pharmews2018-12-03 06:40:53

#PD-(L)1


今日快报

来自BMS

新的Q4W (480 mg)给药方式获FDA批准

该申请来自2017年7月24日提交

也就是说Opdivo临床用药方式

将变得更加灵活



新给药方式获批的适应症如下

仅转移性结直肠癌(mCRC)未在列



顺便来看下现有PD-(L)1的给药方式

对比一下

Q4W目前仅Opdivo获批

这也意味着

Opdivo又有了一个给药优势


At Bristol-Myers Squibb, we are united in our mission to fight cancer from all angles and recognize every patient has unique needs. From the introduction of our first Immuno-Oncology agent through today’s approval of flexible dosing options at two- or four-week intervals, we are relentless in pursuing innovative options for the cancer community. With this approval, we now offer the most robust range of dosing options for an Immuno-Oncology medicine, providing enhanced flexibility to help address each patient’s specific needs.

——Johanna Mercier

head, U.S. Commercial, Bristol-Myers Squibb